Dr. Goodwin has over 15 years experience in management of biomedical development, technology transfer and biomedical product licensing. He has negotiated over 30 licensing deals in the healthcare field. Dr. Goodwin established the technology transfer office at the University of Rochester (NY), which consistently ranks in the top 10 in licensing royalty revenue among university programs in the U.S. He licensed intellectual property covering the HPV VLP vaccine technology to MedImmune that evolved into both GSK’s Cervarix® product and Merck’s Gardasil® product. He also managed an intellectual property portfolio including the Cox-2 gene and the vaccine conjugate technology at the heart of Wyeth’s HibTITER® and Prevnar® products. Dr. Goodwin later directed business development and licensing activities for STS Biopolymers, Inc., a private drug delivery and interventional surgical technology company that was acquired by Angiotech Pharmaceuticals in 2003.
